Mapping research activity on mental health disorders in Europe: study protocol for the Mapping_NCD project by Berg Brigham, Karen et al.
  
Karen Brigham Berg, Meryl Darlington, , John S. F. Wright, 
Grant Lewison, Panos Kanavos and Isabelle Durand-Zaleski 
Mapping research activity on mental health 
disorders in Europe: study protocol for the 
Mapping_NCD project 
 
Article (Published version) 
(Refereed) 
 
Original citation: 
Berg Brigham, Karen, Darlington, Meryl, Wright, John S. F., Lewison, Grant, Kanavos, Panos 
and Durand-Zaleski, Isabelle (2016) Mapping research activity on mental health disorders in 
Europe: study protocol for the Mapping_NCD project. Health Research Policy and Systems, 14 
(1). ISSN 1478-4505 
 
Reuse of this item is permitted through licensing under the Creative Commons: 
 
© The Author(s) 2016  
CC-BY 4.0 
 
This version available at: http://eprints.lse.ac.uk/66932/ 
Available in LSE Research Online: June 2016 
 
LSE has developed LSE Research Online so that users may access research output of the 
School. Copyright © and Moral Rights for the papers on this site are retained by the individual 
authors and/or other copyright owners. You may freely distribute the URL 
(http://eprints.lse.ac.uk) of the LSE Research Online website.  
 
 
 
STUDY PROTOCOL Open Access
Mapping research activity on mental health
disorders in Europe: study protocol for the
Mapping_NCD project
Karen Berg Brigham1,2*, Meryl Darlington1,2, John S. F. Wright3, Grant Lewison4, Panos Kanavos3,
Isabelle Durand-Zaleski1,2,5 and On behalf of the Mapping_NCD consortium
Abstract
Background: Mental health disorders (MHDs) constitute a large and growing disease burden in Europe, although
they typically receive less attention and research funding than other non-communicable diseases (NCDs). This study
protocol describes a methodology for the mapping of MHD research in Europe as part of Mapping_NCD, a 2-year
project funded by the European Commission which seeks to map European research funding and impact for five
NCDs in order to identify potential gaps, overlaps, synergies and opportunities, and to develop evidence-based
policies for future research.
Methods: The project aims to develop a multi-focal view of the MHD research landscape across the 28 European
Union Member States, plus Iceland, Norway and Switzerland, through a survey of European funding entities, analysis
of research initiatives undertaken in the public, voluntary/not-for-profit and commercial sectors, and expert interviews
to contextualize the gathered data. The impact of MHD research will be explored using bibliometric analyses
of scientific publications, clinical guidelines and newspaper stories reporting on research initiatives. Finally,
these research inputs and outputs will be considered in light of various metrics that have been proposed to
inform priorities for the allocation of research funds, including burden of disease, treatment gaps and cost of
illness.
Discussion: Given the growing burden of MHDs, a clear and broad view of the current state of MHD research is
needed to ensure that limited resources are directed to evidence-based priority areas. MHDs pose a particular challenge
in mapping the research landscape due to their complex nature, high co-morbidity and varying diagnostic criteria.
Undertaking such an effort across 31 countries is further challenged by differences in data collection, healthcare systems,
reimbursement rates and clinical practices, as well as cultural and socioeconomic diversity. Using multiple methods to
explore the spectrum of MHD research funding activity across Europe, this project aims to develop a broad, high-level
perspective to inform priority setting for future research.
Keywords: Mental health, Research activities, Health priorities, Europe
Background
Mental health disorders (MHDs) encompass a broad
range of conditions that together comprise a large and
growing share of the burden of disease in Europe [1].
Despite the significant burden of disease, MHDs
typically receive less attention and funding than other
non-communicable diseases (NCDs). Governments have
begun to recognize this need and are working to address
the burden of MHDs, but developing an evidence-based
future research agenda requires a clear picture of the
current MHD research landscape, including the roles
played by the broad spectrum of funding entities.
Mapping_NCD, a 2-year project funded by the European
Commission, seeks to map research funding and impact in
Europe for five NCDs – cardiovascular disease, respiratory
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disease, cancer, diabetes and MHDs – with the goal of
identifying potential gaps, overlaps, synergies and oppor-
tunities, and proposing evidence-based policies to support
coordinated approaches for NCD research. This study
protocol describes the methodology for mapping MHD
research in Europe.
Analysis of research funding and its impacts is often
carried out on an institutional or national basis, where
allocation may be based on a variety of criteria, such as
research excellence or national disease plans, and impact
analyses often rely upon bibliometric measures. Expand-
ing the scope of such research funding analysis to en-
compass multiple countries and diverse funding entities
requires multiple methods and entails a loss of precision
because of the difficulties in delineating funding flows
for research investments on such a scale. Nonetheless,
estimating the extent and impact of MHD research
funding is an effort worth undertaking. As Donovan
noted, “Impact is a strong weapon for making an evi-
dence based case to governments for enhanced research
support” [2].
The Mapping_NCD project will develop a multi-focal
view of the MHD research landscape by soliciting the
perspectives of European funding entities, analysing the
types of research undertaken in the public, voluntary/
not-for-profit and commercial sectors, and contextualiz-
ing the collected data through expert interviews. In a
second phase, the outputs and impact of MHD research
will be explored using bibliometric analyses of scientific
publications, clinical guidelines and newspaper stories
reporting on research initiatives. Finally, these research
inputs and outputs will be considered in light of various
metrics that have been proposed to inform the allocation
of research funds, including burden of disease, treatment
gaps and cost of illness.
Methods/Design
Scope of the study
The Mapping_NCD project explores the NCD research
activity across 31 European countries: the 28 European
Union Member States (MSs) as well as Iceland, Norway
and Switzerland. MHD research was defined as research
into the causation, occurrence, presentation, diagnosis,
treatments and care of disorders affecting the mental
health of their sufferers in childhood, adolescence, adult-
hood and older age. In order to situate MHD research
within the context of the relative disease burden in
Europe, we will focus on ten specific MHDs for which
the 2013 Global Burden of Disease (GBD) study calcu-
lated the burden as expressed in disability-adjusted life
years (DALYs) [1]: addiction, alcohol use disorders,
Alzheimer’s disease and other dementias, anxiety, bipo-
lar disorder, depression, eating disorders, schizophrenia,
attention deficit hyperactivity disorder and suicide/self-
harm. To ensure as complete a picture of the research
landscape as possible, we will compile and analyse data
regarding the research activity of public, voluntary/pri-
vate non-profit and commercial research funding organi-
zations (RFOs).
The Mapping_NCD project was funded under the
European Commission’s 7th Framework Programme and
was subject to the Commission’s ethics review process
(grant agreement number 602536).
Evidence bases for mapping research activity in Europe
Using an approach that combines quantitative and quali-
tative data, the study will develop multiple evidence
bases with the goal of mapping the current scope and
scale of MHD research funding in Europe. A variety of
tools will be used to capture a broad-based view that en-
compasses the different participants and perspectives
(Fig. 1).
The key element of the initial phase of the project will be
an online survey of RFOs that will gather data on overall
funding levels, disease focus, funding sources and prior-
ities, types of research funded both currently and planned
for the future, and expectations regarding outputs. The
tool will be developed and tested in a pilot phase before be-
ing implemented across the study area. The relevant pub-
lic, non-profit and private RFOs at the regional, national,
supranational and EU levels will be identified through a
systematic search by all consortium members across the
five NCD categories. This organizational structure facili-
tates the identification of RFOs and the collection of survey
data within countries and will enable consortium partners
to overcome language barriers and ensure that data across
the five disease categories are collected on a standardized
basis. A baseline threshold of €0.5 million to €1 million in
annual investment has been set with the goal of identifying
funding that could be expected to influence the content or
direction of major research programmes.
Participation in the survey will be solicited by email or
Internet-based contacts. Additional website interroga-
tions will be undertaken to gather available funding data
for the identified RFOs. All non-responding RFOs will
be followed-up until the close of survey, approximately
9 months after its initiation. After the data are gathered
on a territorial basis, the consortium members will
deliver the survey results to the members charged with
the analysis of each of the five disease categories.
While the overall funding levels of RFOs can provide a
macro level view of MHD research, project-based fund-
ing data provide a rich source of information regarding
disease focus, types of research and project funding
levels. The broad-scale view of European RFOs involved
in MHD research provided by the survey will be comple-
mented by a purposive sample of publicly-funded pro-
jects in the five largest MSs for the period 2006–2013 in
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order to obtain a more focussed picture of research activ-
ity in recent years. The 20 most highly-funded MHD re-
search projects from a key public research funder in each
of the five countries will be identified and analysed. Given
the strong influence of the European Commission in re-
search priority setting, MHD projects funded at the Euro-
pean level for the same period will be analysed. Data will
be extracted from the Cordis database (http://cordis.euro-
pa.eu/home_en.html), including title, timeframe, MHD
focus, type of research and level of funding. Our analysis
will also include country participation, given that previous
studies have found relatively low levels of participation by
the newest MSs in European health-related research [3].
Commercial investment in MHD research is an im-
portant component of the overall research picture, al-
though obtaining detailed and specific data on research
and development (R&D) expenditure is challenging due
to lack of transparency of information considered pro-
prietary. We will focus our efforts on identifying the
MHD products in the pharmaceutical and medical de-
vice pipelines of European and United States companies
for the period 2011–2014.
To measure and compare the commitment of European
and United States pharmaceutical companies to R&D
investment in MHDs, including the specific disease focus,
we will examine the general trends in R&D expenditure,
including total R&D expenditure and as a percentage of
sales or revenues. We will also explore their research
pipelines in terms of MHD molecules in Phase I, II
or III trials. Data for publicly-traded companies will
be collected from the four most recent annual reports
available on the companies’ websites (2011–2014). For
privately-held companies, it is generally possible to obtain
information regarding drug R&D through clinical trial da-
tabases, such as ClinicalTrials.gov. We will consider the
pharmaceutical pipelines of European and United States
companies at three levels: the top 20 companies in terms
of R&D investment as identified by the 2014 EU Industrial
R&D Investment Scoreboard (http://iri.jrc.ec.europa.eu/
scoreboard14.html); companies ranked 100 to 2500 for
R&D on the European Union Scoreboard; and smaller,
mostly privately-held companies. This will enable us to
better understand whether the disease focus and level of
implication in MHD research varies depending on the size
and investment capacity of the company.
To explore the medical device pipelines of the top
medical device manufacturers as ranked by total reve-
nues (http://www.mddionline.com/article/top-40-medica
l-device-companies), data regarding ongoing or com-
pleted trials will be obtained from ClinicalTrials.gov for
the period 2011–2014. Data for medical devices with
FDA pre-market approval or de novo classification will
also be searched for the same period. EUDAMED, the
European database of CE marked products, has
existed since 2009 but is only accessible to govern-
ment agencies charged with market surveillance in
each country. Thus, we will search the database of
the EuroScan International Network, a global network
of publicly funded early awareness and alert systems
for health technologies, in order to identify relevant
MHD devices [4].
For both the pharmaceutical and medical device pipe-
lines, terminated trials and those for which trial status is
unknown or not verified will be excluded.
Fig. 1 Mapping MHD research in Europe
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In order to contextualize the data and knowledge ob-
tained through the preceding methods, we will under-
take semi-structured interviews with key MHD experts
in Europe to obtain their views on the strengths and
weaknesses of the MHD research environment in
Europe. We will use an interview guide with questions
regarding priorities and funding trends in mental health
research, the respective roles and priorities of the public
and private entities, the issue of coordination and redun-
dancy, and initiatives beyond funding that could improve
MHD research in Europe.
Potential interviewees will be identified through pur-
posive sampling with the goal of interviewing a range of
experts with broad knowledge and perspectives on the
MHD research landscape in Europe, including leaders of
RFOs, researchers and policy experts. The recorded and
transcribed interviews will be subject to qualitative ana-
lysis using the Framework Method, a highly systematic
method for categorizing data with a matrix output that
allows descriptive and explanatory conclusions to be
organised by theme [5]. The qualitative data will then be
charted into a framework matrix to allow thematic ana-
lysis across the interviews.
Impact analyses of research
The ultimate goal of health research should be better
clinical care and improved population health. The Map-
ping_NCD project aims to explore the pathway from re-
search investments through to measurable impacts, and
ideally, these impacts would be improvements in popula-
tion health outcomes. However, the time lag from re-
search expenditure to translation into clinical practice is
estimated to be 17 years or longer [6]. Such a timeframe
is beyond the scope of the present study, and thus we
have selected the following proxies to measure the im-
pact of MHD funding investments: scientific publica-
tions, clinical guidelines and newspaper stories.
One way in which research funding is considered to
have had ‘impact’ is by means of knowledge production
through the publication of scientific papers. Thus, we
will identify the number of MHD articles and reviews
through bibliometric analyses of research outputs across
and within the 31 study countries for the period 2002–
2013. Papers will be identified by means of a filter for
which precision and recall will be tested by MHD ex-
perts, who will mark papers as relevant or not. We will
analyse the publication and citation of scientific papers
using the Thomson Reuters Web of Science (WoS) data-
base and citation indexes.
The growth in research output for European MHD
papers over the period will be compared to world MHD
research output as well as to overall biomedical research
output. The output of each country will also be ex-
plored, including the growth rate and the extent of
international collaboration. These data will be further
analysed by Gross Domestic Product (GDP) to deter-
mine variation in outputs based on individual countries’
economies. Finally, we will examine the research outputs
by individual disorders, both across the 31 European
countries and by individual country.
Citation analysis is used in allocating research funds,
including at a central level to distribute funds across
institutions based on aggregate statistics and at an insti-
tutional level to evaluate individual researcher and re-
search groups for purposes of distributing funds within
an institution. Citation analysis will be undertaken on
the identified MHD papers using two overlapping data-
bases, the Science Citation Index Expanded and the
Social Sciences Citation Index. To measure the individual
impact of research papers, 5-year actual citation impact
scores will be used. Fractional counting of citations, such
that a citation in a paper with n addresses would count for
only (1/n)th of overall citations instead of a full point, will
be used in order to facilitate comparison between different
disciplinary affiliations at the paper level.
Analysis of papers referenced in clinical guidelines is an
indicator of how research can inform health practice. It
may also serve as an indicator of the lag time between
research expenditure and potential health benefits as well
as an attribution of the benefits of a particular country’s
research [7]. Papers cited in MHD clinical guidelines in
the 31 study countries will be identified using a macro that
generates search statements to find the publications in the
WoS database. The papers will then be analysed in terms
of timeframe, leading country, research type, systematic
reviews and mean 5-year citation score.
Finally, the results of research may be reported in
news stories, which provide an additional perspective re-
garding the potential impact of research. While medical
stories in the press target the general public, impact on
health behaviours cannot be assumed and indeed may
be positive or negative [8]. Media stories may also influ-
ence healthcare professionals and decision makers and
in turn the policy agenda. Key newspapers in the 31
countries will be selected and their online databases and
archives searched for the period 2002–2013 using sim-
plified queries to identify stories about research involv-
ing one or more of the 10 MHDs. The related scientific
publications will be identified in the WoS database. Ana-
lyses will include the focus of the research, the time-
frame, the extent to which research is reported in
multiple countries, particularly outside of the study
country, and the journals attracting the most extensive
press coverage.
Metrics for priority setting
Various estimates of disease burden are used as metrics
to identify mismatches between research investment and
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societal burden, including mortality, incidence, preva-
lence and most prominently DALYs [9]. The burden
may appear very different depending on the measures
used. For example, alcohol misuse has a high prevalence
but a low rank in terms of years lived with disability,
while schizophrenia reflects the opposite tendency, rank-
ing third for years lived with disability but ninth for
prevalence [1].
Since the first GBD study was launched in 1990, bur-
den of disease as expressed in DALYs has been widely
used as a measure of the relative magnitude of disease at
the country or regional level and has informed debates
about the health sector [10]. A benefit of DALYs as a
metric is the fact that it integrates morbidity and mortal-
ity while also allowing them to be considered separately.
Our analysis will use the 2013 DALYs for the 31 study
countries from the 2013 GBD study by the Institute for
Health Metrics and Evaluation [11].
While we will use MHD disease burden as measured
in DALYs as a key metric in our analyses, it also has lim-
itations, particularly as a means of allocating research
funding, because it fails to account for differences in
resources across countries [12, 13]. Therefore, we will
also consider other measures that may help to inform
research priority setting.
The treatment gap is a measure of unmet need, repre-
senting the absolute difference between the true preva-
lence of a disorder and the treated proportion of
individuals affected by the disorder. Alternatively, the
treatment gap may be expressed as the percentage of in-
dividuals who require care but do not receive treatment.
The excess disability due to MHDs is partially explained
by early age of onset, yet initial treatment is frequently
delayed for many years. Reasons for such delays include
failure to seek help because the problem is not acknowl-
edged, a perception that treatment is not effective, a
belief that the problem will go away on its own or a
desire to deal with the problem without outside help. In
addition, lack of knowledge about mental disorders and
stigma remain major barriers to care. Other factors act
as direct barriers to care, including financial consider-
ations and issues of accessibility, as well as limited or
lack of availability of certain services in some countries
or for some populations. Indeed, MHDs have often been
given a lower priority than physical diseases, although
there are signs that this is beginning to change in
Europe.
A study examined the extent of the treatment gap and
found that, despite the existence of some effective and
cost-effective treatments, many individuals with psychi-
atric disorders remain untreated [14]; 37 studies of treat-
ment gaps were identified worldwide and revealed a
high degree of unmet need for the following MHDs:
schizophrenia (32%), bipolar disorder (50%), major
depression (56%), generalized anxiety (58%) and alcohol
use disorders (78%). We will incorporate this metric into
our analyses of the data acquired for these five MHDs.
Cost of illness is another measure of the societal bur-
den of disease. The European Brain Council (EBC) has
undertaken studies of the costs of brain disorders in
Europe, where 23% of years of healthy life are lost due
to brain diseases at an annual total cost to the region of
€386 billion. In 2005, the EBC published, for the first
time, overall estimates of annual costs for brain disor-
ders in Europe, which were updated and extended to
additional disorders in 2010 [15, 16]. The EBC study was
based on the best data available at the time, and model-
ling allowed extrapolation to countries with paucity of
data, the results of which were found to be consistent
with administrative data on healthcare expenditure in
Europe. Cost of illness estimates, including breakdowns
by country and type of cost (direct and indirect), were
reported for each of the MHDs included in the Map-
ping_NCD study except for attention deficit hyperactiv-
ity disorder and suicide/self-harm, and we will analyse
the MHD research activity and output data collected in
light of the estimated cost of these disorders.
Discussion
Since the publication of the 1990 Global Burden of
Disease study, the burden of MHDs has increased
worldwide [1]. From 1990 to 2013, prevalence of each of
the 10 MHDs included in our study has increased,
sometimes dramatically: Alzheimer’s disease and other
dementias (+88%), schizophrenia (+52%) and anxiety
disorders (+42%). These increases are attributable to
multiple factors, including aging populations, improve-
ments in diagnostic tools, better classification criteria
and improved epidemiological studies, and underscore
the need to develop improved treatments and health
services.
A clearer and more comprehensive picture of the state
of MHD research is essential so that limited resources
may be directed to evidence-based priority areas. How-
ever, MHDs pose a particular challenge in mapping the
research landscape. The complex nature and high co-
morbidity of many MHDs, combined with differences in
methodological standards and diagnostic instruments,
make studies difficult to compare. Capturing and com-
paring overall disease prevalence is further challenged by
variation in data collection, healthcare systems, reim-
bursement rates and clinical practices in European
states. The significant cultural and socioeconomic differ-
ences found across Europe also make it difficult to
generalize results [17]. As Knapp et al. [18] note, “It is
hard – perhaps foolishly heroic – to generalize from
country to country because mental health systems, socio-
demographic structures, cultural contexts, personal
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preferences, political priorities and economic incentives
can be so very different”.
Ideally, it would be possible to trace the beneficial ef-
fects of research funding over time. Indeed, an emerging
field of study concerns estimation of the return on re-
search investment by comparing the accrued economic
benefits with its cost. A United Kingdom study esti-
mated the returns of public and charitable research in
terms of health gains and GDP gains in two therapeutic
areas: cardiovascular disease and mental health [7]. Net
health gains to the United Kingdom population due to
MHD research, computed as the internal rate of return,
were estimated at 7%, while the additional internal rate
of return from GDP gains were 30%, for a total rate of
return of 37%. In other words, a £1.00 investment in
public/charitable MHD research produced a benefit
stream equivalent to £0.37 annually in perpetuity.
One of the most significant challenges in estimating
the return on research investment concerns the lag time
between medical research and its impact. The United
Kingdom study estimated public, charitable and private
pharmaceutical research expenditure for the period 1975
to 1992 and estimated the health gains over the period
1985 to 2005. Undertaking this level of analysis across
the 31 countries in our study would be extremely
resource-intensive and most likely impossible at this
time due to lack of necessary data. However, we raise it
to encourage reflection on the need for standardization
of data and the development of more sophisticated
methodologies to better estimate the benefits of medical
research, particularly for MHDs.
We recognize the challenges we face in our quest to
map MHD research and its impact in Europe and have
attempted to identify the limitations in our method-
ology. The maxim “not everything that counts can be
counted, and not everything that can be counted counts”
applies well to the task of measuring research and its
impact. While data and resource limitations constrain
the depth of our inquiry, we believe that this project will
provide a high-level, multi-focal view of the current
MHD research situation across Europe able to inform
priorities for future research.
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